STEMEDICA BEGINS FIRST CLINICAL TRIALS IN THE U.S. USING ADULT ALLOGENEIC STEM CELLS TO TREAT ALZHEIMER’S DISEASE
Stemedica Cell Technologies, Inc. and its subsidiary, Stemedica International S.A.are pleased to announce the opening of enrollment into a new study at Emory University in Atlanta and University of California, Irvine (UCI).
Stemedica received an FDA investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its ischemic tolerant, adult allogeneic mesenchymal stem-cells (itMSC) to treat subjects with traumatic brain injury (TBI).
DRIVEN BY 30 YEARS OF STEM CELL RESEARCH & SCIENTIFIC ADVANCEMENT
Transforming Medicine for the 21st Century
Stemedica Cell Technologies, Inc., is transforming regenerative medicine through the development and manufacturing of adult ischemic-tolerant stem cell products and biological compounds. Our technology has led us to breakthroughs that are changing medicine and improving life globally. As one of the few companies licensed and approved for clinical grade manufacturing and trial applications by regulatory agencies worldwide, our focus is on producing the best-in-class products available today.